ISRCTN12125882 - Influence of topical anti-VEGF (Ranibizumab) on the outcome of filtration surgery for glaucoma - Study Protocol. - Wikidata - wikimedia - TriplyDB

ISRCTN12125882 - Influence of topical anti-VEGF (Ranibizumab) on the outcome of filtration surgery for glaucoma - Study Protocol.

ISRCTN12125882 - Influence of topical anti-VEGF (Ranibizumab) on the outcome of filtration surgery for glaucoma - Study Protocol.

http://www.wikidata.org/entity/Q33795198

about

Anti-vascular endothelial growth factor for control of wound healing in glaucoma surgery Anti-vascular endothelial growth factor for control of wound healing in glaucoma surgery Recent advances in the management of neovascular glaucoma.Efficacy of intravitreal ranibizumab combined with Ahmed glaucoma valve implantation for the treatment of neovascular glaucoma.Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma.Subconjunctival bevacizumab injection in glaucoma filtering surgery: a case control series.Intravitreal ranibizumab as an adjunct for Ahmed valve surgery in open-angle glaucoma: a pilot study.Anti-VEGF therapy for the treatment of glaucoma: a focus on ranibizumab and bevacizumab.

P2860

Q24186464-E912AD6A-F0D0-48F2-996E-F1069F9BABB3 Q24200772-2BB9CE37-87C3-4F6E-98FA-760734AF9FAC Q34734475-8FBB8015-B4EA-45F8-937F-C5175E0C7809 Q35889573-BCA4D28E-4DE8-456E-BA1B-D2FC49C05531 Q37672460-9F01E71E-7129-4211-B8A7-9BE4DCB44BB3 Q41915240-38DAE19E-9F17-40F7-9A8C-C8A0FE5CF3FC Q46166141-D9F2AF70-742C-4CE3-8627-1AC49BEE058D Q53362175-F08977CD-F009-4A5C-B9F4-DEDA94AF5E00

P2860

ISRCTN12125882 - Influence of topical anti-VEGF (Ranibizumab) on the outcome of filtration surgery for glaucoma - Study Protocol.

http://www.wikidata.org/entity/Q33795198

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

ISRCTN12125882 - Influence of ...... for glaucoma - Study Protocol.

@ast

ISRCTN12125882 - Influence of ...... for glaucoma - Study Protocol.

@en

type

label

ISRCTN12125882 - Influence of ...... for glaucoma - Study Protocol.

@ast

ISRCTN12125882 - Influence of ...... for glaucoma - Study Protocol.

@en

prefLabel

ISRCTN12125882 - Influence of ...... for glaucoma - Study Protocol.

@ast

ISRCTN12125882 - Influence of ...... for glaucoma - Study Protocol.

@en

P1433

Q33795198-C2CD6B49-D54B-449D-AE92-339BDAFC478B

P1476

Q33795198-0C07A472-8529-4610-ACF6-6AFC0E48D382

P2093

Q33795198-023E1C68-F705-45B1-A3DF-F2559DEBFDAA

Q33795198-0E039D5E-A270-4348-983F-C1D71FDC9CD2

Q33795198-962DFE38-EBFD-427E-B57D-0711098DCE92

Q33795198-A9C13709-D061-42FE-B8EF-BC37D02D670C

Q33795198-AA383795-675A-440F-8D14-07BA7CD154EA

Q33795198-CC6EFB87-8FFC-4844-B959-B45624DDFC90

Q33795198-EAB442B8-D8AB-4384-A928-114C46767503

P2860

Q33795198-16B4A043-E939-484C-A954-E3AC5A943C1E

Q33795198-3C38A069-DA6E-4663-A5C6-FA374718F664

Q33795198-5B86AF01-6F02-4911-9267-CDA285D825C6

Q33795198-5BE4EF23-4028-4D7D-BDBA-B15E03EA30CA

Q33795198-642B50DD-419D-4845-AF73-FF469DD47963

Q33795198-6D50D5C7-A20D-44EE-8EAE-15372C791AC3

Q33795198-6ECC88BA-F864-46CA-8329-321A78058BE1

Q33795198-87D524C9-37CA-4D74-A10F-2F7999D1031E

Q33795198-8C0F31AD-CC8A-43C4-A468-2DC2E35C8642

Q33795198-940C7E32-EA2D-4107-A63A-E40652307222

P2888

Q33795198-D26C19EF-12EE-4D1A-8E05-95162C8EE177

P304

Q33795198-B140A08D-B012-4397-8BBF-19BB4E032C1B

P31

Q33795198-FABE4254-19DC-41D5-845C-4D0CBE0EE7D0

P356

Q33795198-A023A619-5CBF-4C52-9B90-54A8A0CA057E

P478

Q33795198-42AE1AEF-8D18-45ED-9CE8-74E8C2766670

P577

Q33795198-1D53BE8B-4D84-480A-9226-6B2C7B6795DA

P5875

Q33795198-B8CE8E8C-E9B8-43D7-B31F-BE63319E6E5C

P6179

Q33795198-E7B6E909-F770-4AAF-A588-24F32BA1E75B

P698

Q33795198-1CC8DC16-27D5-4BAC-9E49-DDB5338203B6

P932

Q33795198-F24A1070-4C2C-40A1-898E-EC47C8DE9FBE

P356

P1433

BMC Ophthalmology

P1476

ISRCTN12125882 - Influence of ...... for glaucoma - Study Protocol.

@en

P2093

Christoph N Becht

http://www.w3.org/2001/XMLSchema#string

Claude Kaufmann

http://www.w3.org/2001/XMLSchema#string

Frank Bochmann

http://www.w3.org/2001/XMLSchema#string

Ivo Guber

http://www.w3.org/2001/XMLSchema#string

Lucas M Bachmann

http://www.w3.org/2001/XMLSchema#string

Michael A Thiel

http://www.w3.org/2001/XMLSchema#string

Michael Kaiser

http://www.w3.org/2001/XMLSchema#string

P2860

Ranibizumab for neovascular age-related macular degeneration

A prospective randomized trial comparing intraoperative 5-fluorouracil vs mitomycin C in primary trabeculectomy.

Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.

Intravitreal bevacizumab in a patient with neovascular glaucoma.

Needle bleb revision of encapsulated filtering bleb with bevacizumab.

Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.

Managing patients treated with bevacizumab combination therapy.

T lymphocyte mediated lysis of mitomycin C treated Tenon's capsule fibroblasts.

Upregulation of transforming growth factor-beta1 and vascular endothelial growth factor in cultured keloid fibroblasts: relevance to angiogenic activity.

Outcomes of primary phakic trabeculectomies without versus with 0.5- to 1-minute versus 3- to 5-minute mitomycin C.

P2888

P304

1

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2415-11-1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49761659

http://www.w3.org/2001/XMLSchema#string

P6179

1002497361

http://www.w3.org/2001/XMLSchema#string

P698

21241468

http://www.w3.org/2001/XMLSchema#string

P932

3034719

http://www.w3.org/2001/XMLSchema#string